Recent studies suggested that CaSR may mediate hypoxic PH through the enhanced CaSR activity 8 and increased CaSR expression level. 9 We then performed the subsequent yeast 
T
here is no any medication to date available for the treatment of hypoxic pulmonary hypertension (PH), a severe disease belonging in group 3 of World Health Organization classification of PH. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/ RELMα) is a secretory protein and inflammatory cytokine, [1] [2] [3] the expression of which is inducible under hypoxia only in lung tissues, including pulmonary vascular cells. 4 HIMF induces the constriction of pulmonary artery (PA) 4 and proliferation of smooth muscle cells 4 and, thus, becomes important for the development of hypoxia-induced pulmonary vascular remodeling and hypertension. 5, 6 HIMF can stimulate a Ca signaling typically mediated by a G protein-coupled receptor (GPCR), 7 implying that HIMF may participate in hypoxic PH through a GPCR-associated mechanism(s). However, the identity of the GPCR and the mechanistic manner for HIMF to affect its activity remain unknown. Several types of GPCR in PA smooth muscle cells (PASMCs) have been revealed to mediate hypoxic PH, and these include the prostaglandin E receptor 3, apelin receptor, 5-hydroxytryptamine receptor 2B, endothelin receptor type A, purinergic receptor P 2 Y 12 , angiotensin II receptor type 1, thromboxane A2 receptor, adrenoceptor alpha 1A, opioid receptor kappa 1, adenosine A2b receptor, and extracellular calcium-sensing receptor (CaSR). We examined whether HIMF served as a classical ligand for a GPCR in an autocrine mode or acted in an alternative manner before its secretion to extracellular space in PASMCs. Considering that protein-protein interaction may be the common pathway whatever HIMF affects the GPCR extracellularly or intracellularly, we accordingly performed coimmunoprecipitation to analyze any potential interaction between HIMF and the GPCR candidates and identified CaSR as the binding partner for HIMF.
2-hybrid assay and unexpectedly revealed that HIMF bound to the intracellular, not the extracellular, domain of CaSR. Furthermore, the binding of HIMF enhanced CaSR activity and mediated hypoxia-evoked proliferation of PA smooth cells and the development of pulmonary vascular remodeling and PH. A synthesized membrane-permeable peptide flanking the core amino acids of the intracellular binding domain of CaSR specifically inhibited hypoxia-enhanced CaSR activity and attenuated the development of hypoxic PH.
Material and Methods

Ethical Approval
We obtained approval for all the experiments involving SpragueDawley rats from the Institutional Animal Care and Use Committee of Tongji Medical College and conducted the experiments following the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Materials
The antibodies used for immunoprecipitation and Western blots were commercially obtained from Abcam for apelin receptor, Abclonal for angiotensin II receptor type 1, Abclonal for adrenoceptor alpha 1A, Santa Cruz for adenosine A2b receptor, Abcam for opioid receptor kappa 1, Abcam for endothelin receptor type A, Abclonal for 5-hydroxytryptamine receptor 2B, Proteintech for purinergic receptor P2Y12, Proteintech for prostaglandin E receptor 3, Abcam for thromboxane A2 receptor, and Lifespan Bioscience for HIMF. The antibody was purchased from Abclonal for CaSR Western blots and Thermo for CaSR immunoprecipitation and 2 antibodies from Sigma for FLAG Western blots and immunoprecipitation, respectively. The antibody against HIMF was selected following the guide from a previous study. 10 All other regents and materials were obtained from Sigma except for specific statement.
Expression of HIMF and Mutated CaSR
The synthesized cDNA of rat HIMF, CaSR, and mutated CaSR fused with flag was cloned into the lentivirus overexpression vector plvxpuro (Clontech) through EcoRI and bamHI, respectively. The correct cloning was verified by sequence, and the vector was packed with lentivirus as described earlier. 8, [11] [12] [13] For overexpression, 0.5 mL of lentivirus (×10 8 TU/mL) was injected into each rat via the respiratory tract. The effectiveness of lentivirus was confirmed by Western blot or ELISA ( Figure S1 in the online-only Data Supplement).
Animal Model and Treatment
Adult male Sprague-Dawley rats weighing 180 to 200 g were exposed to 10% O 2 8 hours a day for 4 weeks in a chamber (0.3 m 3 size, 10 rats per chamber). [14] [15] [16] [17] [18] The oxygen content in the chamber was balanced with N 2 ventilation and continuously monitored by an oxygen meter, and soda lime and silica gel were used to absorb CO 2 and water. For control, animals were raised in the same chamber with air ventilation.
From 1 to 28 days, the rats were either intraperitoneally injected with vehicle or Calhex231 (4- 
at 410 μg/kg every day or injected through tail vein with peptide 3 at 2 mg/kg every other day. The increased HIMF expression in PA over time after exposure to hypoxa was noted ( Figure S2 ).
The rat PASMCs were cultured from the intralobar artery explants of male Sprague-Dawley rats as previously described. 8, 12 [Ca 2+ ] i and the sensitivity of CaSR were measured in PASMCs using Fura-2 AM (Fura-2-acetoxymethyl ester; Invitrogen) as reported earlier. 8, 12 The expression of shRNA against rat CaSR and HIMF in cultured PASMCs in vitro and in lung in vivo via the respiratory tract was conducted following our previous procedures. 8, [11] [12] [13] Hemodynamic studies were performed as we recently delineated. 8, 13 The synthesis of cell-permeable peptides and more details of the above experimental procedures have been provided in the online-only Data Supplement.
Statistical Analysis
Data were reported as means±standard errors. The Student's t test and 1-way analysis of variance were made for 2 or multiple group comparisons, respectively. A P<0.05 was considered to be significantly different.
Results
CaSR Is a Binding Partner for HIMF
To screen the potential partner for HIMF, we performed coimmunoprecipitation on the tissue protein lysed from PAs of rat after 4 weeks of exposure to hypoxia. We immunoprecipitated the lysate using an antibody against the GPCR known to be involved in the development of PH, which included prostaglandin E receptor 3, 19 apelin receptor, 20 5-hydroxytryptamine receptor 2B, 21 endothelin receptor type A, 22 purinergic receptor P2Y12, 23 angiotensin II receptor type 1, 24 thromboxane A2 receptor, 25 adrenoceptor alpha 1A, 26 opioid receptor kappa 1, 18 adenosine A2b receptor, 27 and CaSR. 8, 9 The subsequent immunoblotting with an antibody against HIMF revealed CaSR as the only binding partner among the above candidates ( Figure 1A) .
To confirm the above finding, we conducted coimmunoprecipitation again on cell lysates from PASMCs and tissue extracts from PAs of rats after exposure to hypoxia. The cross pull-down and probing with antibody against CaSR and HIMF, respectively, showed the binding of CaSR to HIMF from each other ( Figure 1B and 1C for PASMCs and PAs, respectively). Our immunochemical stainings on PASMCs and PAs demonstrated the overlap of immunofluorescence between CaSR and HIMF, providing additional evidence for their binding to each other ( Figure 1D and 1E for PASMCs and PAs, respectively). The above experiments also revealed an obviously increased expression of CaSR and HIMF in PASMCs and PAs after hypoxic exposure (Figure 1 ), which is completely in agreement with previous reports. 9 To determine the domain and amino acids for CaSR binding to HIMF, we performed the yeast 2-hybrid based on the DUAL membrane pairwise interaction assay. First, the obviously enhanced activity of β-galactosidase reporter revealed an interaction between full-length CaSR and HIMF ( Table S1 ).
CaSR and HIMF Interaction Mediates Chronic Hypoxia-Induced Pulmonary Hypertension
To explore the potential significance of CaSR and HIMF interaction, we first evaluated the contribution of CaSR and HIMF on its own to the development of hypoxic PH. We found that intermittent hypoxia (daily 8 hours for 4 weeks) obviously enhanced the sensitivity of CaSR, and hypoxiapromoted proliferation of PASMCs, the development of PH, and the hypertrophy of PAs and right ventricle were attenuated either by CaSR inhibitor, Calhex231 or CaSR knockdown ( Figures S3 and S4 ), or by HIMF knockdown (Figure 3 ). The results indicated that both CaSR and HIMF did contribute to the development of hypoxic PH in the current experimental condition, which were completely consistent with previous reports. 5, 6, 8, 28 Our subsequent experiments further showed that hypoxia-enhanced CaSR sensitivity was attenuated by HIMF knockdown, and HIMF overexpression also enhanced CaSR sensitivity ( Figure 3A) , and that HIMF overexpressioninduced proliferation of PASMCs and PH was attenuated by Calhex231 and by CaSR knockdown ( Figure 3B and 3C). These findings, thus, provided the clue for the mechanistic role of CaSR and HIMF interaction in hypoxic PH. The immunoprecipitation screen of G protein-coupled receptor (GPCR) potentially interacted with hypoxia-induced mitogenic factor (HIMF). A, The protein lysate from pulmonary arteries (PAs) of rat after 4 weeks exposure to hypoxia was immunoprecipitated with an antibody against the GPCR of apelin receptor (APLNR), angiotensin II receptor type 1 (AGTR1), Abclonal for adrenoceptor alpha 1A (Adra1a), adenosine A2b receptor (Adora2b), calcium-sensing receptor (CaSR), endothelin receptor type A (EDNRA), 5-hydroxytryptamine receptor 2B (Htr2b), opioid receptor kappa 1 (Oprk1), purinergic receptor P2Y12 (P2ry12), prostaglandin E receptor 3 (Ptger3), or thromboxane A2 receptor (Tbxa2r), respectively, and then probed by an anti-HIMF antibody (n=3). B and C, The cross immunoprecipitation (IP) and probing with antibody against CaSR (170 KDa) and HIMF (immune blot [IB]), respectively, on lysates from pulmonary artery smooth muscle cells (PASMCs) and PAs of rats after exposure to hypoxia (n=6 for each). D and E, Immunochemical stainings on PASMCs and PAs of rats after exposure to hypoxia (n=6 and 5 for D and E, respectively).
Our experiments showed that the expression of the intracellular domain of CaSR with mutated aa of 885 to 888 (CaSR-M) profoundly inhibited the binding of HIMF to CaSR ( Figure 4A) Figure 4B ), and proliferation of PASMCs ( Figure 4C ). These results not only proved the critical role of 885 to 888 aa in the binding of HIMF to CaSR as revealed from yeast 2-hybrid experiments (Figure 2 ), but also provided an additional line of evidence for the cellular significance of HIMF binding to CaSR in hypoxia-enhanced CaSR sensitivity and proliferation of PASMCs. Furthermore, they rendered a possible strategy to directly evaluate the importance of HIMF binding with CaSR in PH. We, thus, expressed CaSR-M in rats by lentivirus transduction 10 and found that CaSR-M also prevented HIMF from binding to CaSR in PAs of rats exposed to hypoxia ( Figure 4D ) and effectively attenuated the development of PH ( Figure 4E ).
Synthesized Peptide Interrupting the Interaction Between HIMF and CaSR Attenuates Chronic Hypoxia-Induced Pulmonary Hypertension
To seek a more easy or feasible-to-handle technique to interrupt the binding of HIMF to CaSR, we designed and synthesized peptides flanking 885 to 888 aa of CaSR intracellular domain, the core for HIMF to bind with CaSR. After being conjugated with a membrane-permeable sequence for penetrating into the cytosol ( Figure 5A ), we introduced the peptides into PASMCs intending to compete with endogenous CaSR for the binding of HIMF. We performed coimmunoprecipitation to screen 3 ] o ) from 1.0 to 2.5 mmol/L in normoxic and 24-hour hypoxiaexposed PASMCs treated with or without HIMF shRNA, as well as HIMF overexpressed PASMCs (HIMF OV) under normoxia with or without treatment of Calhex231 or CaSR shRNA and the statistical summary (n below the bar indicates the total number of PASMCs examined from at least 3 independent experiments, *P<0.01). B, The relative proliferation rate of PASMCs in response to 1% O 2 for 24 hours in PASMCs treated with or without HIMF shRNA or in HIMF overexpressed PASMCs under normoxia with or without treatment of Calhex231 or CaSR shRNA (n=3 for each; *P<0.01 #P<0.05). PASMCs seeded at 2000 per well were cultured for 24 hours, starved for an additional 24 hours in serum-free medium, and then exposed to hypoxia or normoxia for 24 hours and finally evaluated for proliferation using the Cell Counting Kit 8, the proliferation rate was expressed as the percentage of normoxia control. Duplicate measurement for each. C, After 4 weeks exposure to hypoxia or after HIMF overexpression under normoxia, hemodynamics were evaluated in SpragueDawley (SD) rats with or without treatment of HIMF shRNA or CaSR inhibitor, Calhex231, or CaSR shRNA for the mean pressure of pulmonary artery (Ppa), pulmonary vascular resistance (PVR), pressure of systemic artery (Psa), and right ventricle (RV) hypertrophy (right ventricular weight/left ventricular+septal weight, RV/LV+S), and then hematoxylin-eosin staining of lung tissues were conducted to assess hypertrophy of pulmonary arteries of 50 to 100 μm diameter and neomuscularization of small vessels (<30 μm; medial thickness percent). n=5, *P<0.01, #P<0.05.
peptides and identified the peptide 3, the most effective one in disrupting the interaction between CaSR and HIMF in hypoxiaexposed PASMCs ( Figure 5B ] o ) from 1.0 to 2.5 mmol/L in PASMCs expressing CaSR-flag and CaSR M-flag after a 24-hour hypoxic exposure and the statistical summary (n in the bar indicates the total number of PASMCs examined from at least 3 independent experiments; *P<0.01). C, The relative proliferation rate of PASMCs in response to 1% O 2 for 24 hours in PASMCs expressing CaSR-flag and CaSR M-flag (n=3 for each; *P<0.01). D, The cross immunoprecipitation (IP) and probing with antibody against CaSR-flag and HIMF (IB), respectively, on lysates of pulmonary arteries (PAs) from hypoxia-exposed rats after expressing CaSR-flag and CaSR M-flag (n=5 for each). E, After 4 weeks exposure to hypoxia, hemodynamics was evaluated in Sprague-Dawley (SD) rats expressing CaSR-flag and CaSR M-flag for the mean pressure of pulmonary artery (Ppa), pulmonary vascular resistance (PVR), pressure of systemic artery (Psa), and right ventricle (RV) hypertrophy (right ventricular weight/left ventricular+septal weight, RV/LV+S), and hematoxylin-eosin staining of lung tissues were conducted to assess hypertrophy of pulmonary arteries of 50 to 100 μm diameter and neomuscularization of small vessels (<30 μm; medial thickness percent). n=5, *P<0.01, #P<0.05. ] o ) from 1.0 to 2.5 mmol/L in normoxia PASMCs and hypoxia-exposed PASMCs with or without a 24 hours incubation with 10 μM membrane-permeable peptide3 and the statistical summary (n below the bar indicates the total number of PASMCs examined from at least 3 independent experiments; *P<0.01). D, The relative proliferation rate of normoxia PASMCs and hypoxia-exposed PASMCs preincubated with or without 10 μM membrane-permeable peptide 3 (n=3 for each; *P<0.01, #P<0.05). E, The cross immunoprecipitation (IP) and probing with antibody against CaSR (170 KDa) and HIMF (IB), respectively, on lysates of pulmonary arteries from 4 weeks hypoxia-exposed Sprague-Dawley (SD) rats treated with membrane-permeable peptide 3 (n=6 for each). F, After 4 weeks exposure to hypoxia, hemodynamics was evaluated in SD rats treated with membrane-permeable peptide 3 for the mean pressure of pulmonary artery (Ppa), pulmonary vascular resistance (PVR), pressure of systemic artery (Psa), and right ventricle (RV) hypertrophy (right ventricular weight/left ventricular+septal weight, RV/LV+S), and then hematoxylin-eosin staining of lung tissues were conducted to assess hypertrophy of pulmonary arteries of 50 to 100 μm diameter and neomuscularization of small vessels (<30 μm; medial thickness percent). n=5 to 7, *P<0.01, #P<0.05.
≈155.34 to 209.32 nmol/L for the presence or absence of peptide 3, respectively; P<0.05; Figure 5C ) and proliferation of PASMCs ( Figure 5D ). Furthermore, the administration of peptide 3 into rats significantly blocked the interaction of CaSR and HIMF in PAs ( Figure 5E ) and the development of PH after chronic exposure to hypoxia ( Figure 5F ). The penetration of peptide 3 into rat smooth muscle layer of PA in situ was confirmed by tracking the rhodamine-labeled peptide 3 ( Figure S5 ).
HIMF Binding Induces the Dimerization of CaSR and HIMF Dimers
To address how the interaction between HIMF and CaSR enhanced the CaSR activity (Figures 3 through 5) , we performed Western blots to analyze the dimerization of CaSR, the critical step for the activation of CaSR. 29 As shown in Figure 6A , both the overexpression of HIMF in normoxic rats and the hypoxic exposure significantly increased the dimer(s) of CaSR. Furthermore, the hypoxia-increased dimerization of CaSR was obviously reversed by HIMF knockdown, by CaSR mutation in its binding core, or by the membrane-permeable peptide 3.
HIMF Dimers of Itself
To address how the binding of HIMF caused the dimerization of CaSR, we detected whether HIMF can dimer by itself. 30 Being completely consistent with the previous report in 3T3-L1 preadipocytes, 30 our Western blot clearly showed the dimerization of HIMF itself when the cell lysate of hypoxiaexposed PASMCs ( Figure 6B ) or purified HIMF ( Figure S6 ) was prepared in nonreduced condition.
Thus, hypoxia induced the expression of HIMF, HIMF then bound to CaSR at its intracellular domain and subsequently promoted the dimerization of CaSR through the dimerization of HIMF itself, which in turn enhanced its sensitivity and ultimately led to the activation of CaSR from the binding of its ligand, the [Ca 2+ ] o .
Specificity of Synthesized Peptide 3 in Attenuating the Enhanced CaSR Sensitivity
To determine any potential or side effect of synthesized peptide 3 on the physiological status of CaSR, we monitored the CaSR activation in PASMCs after a jump of [Ca 2+ ] o concentration to 6.0 mmol/L, an established condition to evaluate the CaSR sensitivity in this type of cell. Calhex231 (a jump of 
Discussion
The findings of the current study can provide mechanistic insights for intracellular HIMF-induced signaling and downstream events. This may cover the onset of the typical Ca 2+ signaling through GPCR activation, the production of inflammatory mediators, and the constriction and proliferation of PASMCs as functional end points for the development of hypoxic PH. HIMF evoked several signaling cascades, including nuclear factor-κB activation, 31 interleukin-4 2,3 and interleukin-6 expression, 32 and vascular endothelial growth factor production. 1 Similarly, CaSR stimulation also induced the activation of nuclear factor-κB, 33, 34 elevated interleukin-4 34 and interleukin-6 expression or secretion, 33 and enhanced vascular endothelial growth factor production. 35 HIMF induced constriction of PA, 4 proliferation of PASMCs, 4 and mediated chronic hypoxia-induced pulmonary vascular remodeling. 5, 6 Correspondingly, CaSR activation also induced the constriction of PA 8 and mediated hypoxia-promoted proliferation of PASMCs and pulmonary vascular remodeling.
9,28 HIMF acted as a proinflammatory cytokine or mediator, [1] [2] [3] and CaSR also served as a critical trigger for inflammasome activation. 36 The above signaling pathways and downstream events induced by HIMF appear well shared with CaSR activation-mediated ones. This may support the overall conclusion of this study about the role of CaSR in mediating intracellular HIMFinduced cellular events and the development of hypoxic PH. Of note, the extracellular application of HIMF-induced Ca 2+ signaling in PASMCs cannot be eliminated by CaSR inhibitor or knockdown ( Figure S7 ), implying that extracellular HIMF may act as a classical ligand for an unknown GPCR. Thus, HIMF may contribute to the development of PH through both extracellular and intracellular pathways depending on its distribution(s) associated with cellular space. Before its secretion to extracellular space, intracellular HIMF can enhance the activity of CaSR through its interaction with the intracellular domain of CaSR, and when it secrets to extracellular space, HIMF can also activate another GPCR(s).
The induced expression of HIMF by hypoxia makes it unlikely to be involved in acute hypoxia-stimulated pulmonary vasoconstriction 4, 7 ; however, this cannot exclude its involvement in chronic hypoxia-sustained pulmonary vasoconstriction. 4, 7 CaSR seems to be involved both in acute hypoxia-stimulated and chronic hypoxia-sustained pulmonary vasoconstriction. 8 Thus, HIMF may exert its role in chronic hypoxia-induced cellular events through its interaction with CaSR. CaSR can independently take part in acute hypoxia-initiated cellular response, such as pulmonary vasoconstriction. 8 On the other hand, HIMF might also exert its role in CaSR-independent manner. A recent study showed that hypoxia-inducible factor 1α worked as a downstream mediator for HIMF-induced PH. 32 To date, there is no literature showing that CaSR activation induced the expression of hypoxia-inducible factor 1α.
This study is the first demonstration for the enhancement of CaSR sensitivity and the subsequent activation through its intracellular domain bound by an endogenous partner, which is not a classical small G protein or a classical ligand bound to its extracellular domain. The motif of CaSR 885 to 888 aa and its neighboring region seem to be a functional domain for CaSR-dependent signaling. 37, 38 Mutations in CaSR 880 to 883 aa significantly reduced calcium response and phospholipase C activation, 37, 38 and CaSR 877 to 891 aa may constitute a putative α-helical structure, 38 a featured one for GPCR-mediated transmembrane signaling. The dimerization-enhanced sensitivity has been well known and well established for GPCR, including CaSR. 29 Therefore, the enhanced CaSR activity probably resulted from its dimerization, which in turn was induced by the binding of HIMF (Figure 6 ). Regarding the HIMF binding-induced dimerization of CaSR, the oligomerization of HIMF by itself ( Figure 6 ) and or comformational changes may be the underlying reason(s).
The effectiveness of membrane permeable peptide(s) flanking intracellular binding domain of CaSR in blocking the interaction between CaSR and HIMF and attenuating the development of hypoxic PH may be exploited for those seeking a novel therapeutic or preventive strategy for this disease. Their advantage superior to the inhibitor of CaSR may be expected to be specific blockage of hypoxia-induced pathological events, without interference with the regular or physiological status of CaSR under normoxia. One limitation of this study may be the model of PH induced by intermittent, not continuous, hypoxia, which was used by many more investigators.
Perspectives
The findings of the current study reveal a novel mechanism underlying the orchestrated roles of HIMF and CaSR in the development of hypoxic PH. It may warrant further translational study exploiting the intracellular binding motif of CaSR with HIMF as a therapeutic target for the treatment of hypoxic PH, an incurable disease.
